HAZARDOUS DRUG EXPOSURES IN HEALTHCARE

Environmental sampling is a relatively new approach used to determine the level of workplace contamination by antineoplastic agents. The procedure has been used extensively in other situations, especially for monitoring contamination by radioactive materials. Typically, work surfaces are sampled with a moistened wipe and the material is extracted and analyzed for specific antineoplastic agents. Currently, it is possible to identify and quantitate six to eight agents with this technique.

• Acampora A, Castiglia L, Miraglia N, Pieri M, Soave C, Liotti F and Sannolo N. A case study: Surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Ann Occup Hyg. 2005; 49:611-618.
• Alexander K, Northrup N, Clarke D, Lindell H and Laver T. Engineering controls in veterinary oncology: a survey of 148 ACVIM board-certified oncologists and environmental surveillance in 20 specialty hospitals. Vet Comp Oncol 2018; 16:385-391.
• Ametsbichler P, Böhlandt A, Nowak D and Schierl R. Occupational exposure to cisplatin/oxaliplatin during Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)? Eur J Surg Oncol 2018; 44:1793-1799.
• Bartel SB, Tyler TG and Power LA. Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs. Am J Health Syst Pharm 2018; 75:199-211.
• Berruyer M, Tanguay C, Caron NJ, Lefebvre M and Bussieres JF. Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: a 2013 follow-up study. J Occup Environ Hyg. 2015; 12:87-94.
• B’Hymer C, Connor T, Stinson D and Pretty J. Validation of an HPLC-MS/MS and wipe procedure for mitomycin C contamination. J Chromatogr Sci. 2015; 53:619-624.
• Bigelow S, Schulz H, Dobish R and Chambers CR. Antineoplastic agent workplace contamination study: the Alberta Cancer Board Pharmacy perspective Phase III. J Oncol Pharm Practice. 2009; 15:157-160.
• Bobin-Dubigeon C, Aminad M, Percheron C, Audeval C, Rochard S, Leynia P and Bard JM. A new validated wipe-sampling procedure coupled to LC-MS analysis for the simultaneous determination of 5-Fluorouracil, Doxorubicin and Cyclophosphamide in surface contamination. J Anal Toxicol. 2013; 37:433-439.
• Bourget P, Amin A, Vidal F, Merlette C, Troude P and Baillet-Guffroy A. The contribution of Raman spectroscopy to the analytical quality control of cytotoxic drugs in a hospital environment: eliminating the exposure risks for staff members and their work environment. Int J Pharm. 2014; 470:70-76.
• Breukels O, van der Gronde T, Simons-Sanders K and Crul M. Antineoplastic drug contamination on the outside of prepared infusion bags. IJPC Intern J Pharmaceutical Compounding 2018; 22:345-349.
• Burton LC and James CA. Rapid method for the determination of ifosfamide and cyclophosphamide in plasma by high-performance liquid chromatography with solid-phase extraction. J Chromatog. 1988; 431:450-454.
• Bussières JF, Theoret Y, Port-Labarthe and Larocque D. Program to monitor surface contamination by methotrexate in a hematology-oncology satellite pharmacy. Am J Health-Syst Pharm. 2007; 64:531-535.
• Bussieres JF, Tanguay C, Touzin K, Langlois E and Lefebvre M. Environmental contamination with hazardous drugs in Quebec hospitals. Can J Hosp Pharm. 2012; 65:428-435.
• Castiglia L, Miraglia N, Pieri M, Simonelli A, Basilicata P, Genovese G, Guadagni R, Acampora A, Sannolo N and Scafarto MV. Evaluation of occupational exposure to antiblastic drugs in an Italian hospital oncological department. J Occup Health. 2008; 50: 48-56.
• Cavallo D, Ursini CL, Perniconi B, Francesco AD, Giglio M, Rubino FM, Marinaccio A and Iavicoli S. Evaluation of gentotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mutat Res. 2005; 587:45-51.
• Chu WC, Hon C-Y, Danyluk Q, Chua PPS and Astrakianakis G. Pilot assessment of the antineoplastic drug contamination levels in British Columbia hospitals pre- and post-cleaning. J Oncol Pharm Practice. 2012; 18:46-51.
• Connor TH Anderson RW, Sessink PJM, Broadfield L and Power LA. Surface contamination with antineoplastic agents in six cancer treatment centers in the United States and Canada. Am J Health-Syst Pharm. 1999; 56: 1427-1432.
• Connor TH and Smith JP. New approaches to wipe sampling methods for antineoplastic and other hazardous drugs in healthcare settings. Pharm Technol Hosp Pharm. 2016; 1:107-114.
• Connor TH, Shults M and Fraser MP. Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23 and 37º C using a desiccator technique. Mutat Res. 2000; 470:85-92.
• Connor TH, Van Balen P and Sessink PJ. Monitoring for hazardous drugs in the operating room. Ann Surg Oncol. 2002; 10:821-822 (comment).
• Connor TH, Anderson RW, Sessink PJ and Spivey SM. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health-Syst Pharm. 2002; 59: 68-72.
• Connor TH, Sessink PJM, Harrison BR, Pretty JR, Peters BG, Alfaro RM, Bilos A, Beckmann G, Bing MR, Anderson LM and DeChristoforo R. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: Results of three studies. Am J Health-Syst Pharm. 2005; 62:475-484.
• Connor, TH. External contamination of antineoplastic drug vials. Hosp Pharm Eur. 2005; Nov/Dec: 52-54.
• Connor TH, DeBord G, Pretty JR, Oliver MS, Roth TS, Lees PSJ, Krieg EF, Rogers B, Escalante CP, Toennis CA, Clark JC, Johnson B and McDiarmid MA. Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J Occup Environ Med. 2010; 52:1019-1027.
• Connor TH, Zock MD and Snow AH. Surface wipe sampling for antineoplastic (chemotherapy) and other hazardous drug residue in healthcare settings: methodology and recommendations. J Occup Environ Hyg. 2016; 13:658–667.
• Couch J, Gibbins J and Connor TH. Evaluation of chemotherapy drug exposure at a veterinary teaching hospital in Michigan. J Occup Environ Hyg. 2013;10:D45-D51.
• Cox J, Speed V, O’Neal S, Hasselwander T, Sherwood C, Eckel SF and Zamboni WC. Development and evaluation of a novel product to remove surface contamination of hazardous drugs. J Oncol Pharm Pract 2015 (epub ahead of print) DOI:10.1177/1078155215621151.
• Crauste-Manciet S, Sessink PJM, Ferrari S, Jomier J-Y and Brossard D. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg. 2005; 49:619-628.
• Crul M and Simons-Sanders K. Carry over of antineoplastic drug contamination in Dutch hospital pharmacies. J Oncol Pharm Pract 2018; 24:483-489.
• Dal Bello F, Santoro V, Scarpino V, Martano C, Aigotti R, Chiappa A, Davoli E and Medana C. Antineoplastic drugs determination by HPLC-HRMSn to monitor occupational exposure. Drug Test Anal. 2016; 8:730-737.
• Delporte JP, Chenoix P and Hubert P. Chemical contamination of the primary packaging of 5-fluorouracil RTU solutions commercially available on the Belgian market. Eur Hosp Pharm. 1999; 5:119-121.
• deWerk Neal A, Wadden RA and Chiou WL. Exposure of hospital workers to airborne antineoplastic agents. Am J Hosp Pharm. 1983; 40:597-601.
• Dorr RT and Alberts DS. Topical absorption and inactivation of cytotoxic anticancer agents in vitro. Cancer. 1992; 70 (supp 4): 983-987.
• Dugheri S, Bonari A, Pompilio I, Boccalon P, Tognoni D, Cecchi M, Ughi M, Mucci N and Arcangeli G. Analytical strategies for assessing occupational exposure to antineoplastic drugs in healthcare workplaces. Medycyna Pracy 2018; 69:589-604.
• Fabrizi G, Fioretti M, Rocca LM and Curini R. DESI-MS2: a rapid and innovative method for trace analysis of six cytostatic drugs in health care setting. Anal Bioanal Chem. 2012; 403:973-983.
• Favier B, Rull FM, Bertucat H, Pivot C, LeBoucher G, Charlety D, Dubois V, Veyre MC, Ardiet C and Latour JF. Surface and human contamination with 5-fluorouracil in six hospital pharmacies. J Pharmacie Clinique. 2001; 20; 157-162.
• Favier B, Gilles L, Ardiet C and Latour JF. External contamination of vials containing cytotoxic agents supplied by pharmaceutical manufacturers. J Oncol Pharm Practice. 2003; 9:15-20.
• Favier B, Gilles L, Latour JF, Desage M and Giammarile F. Contamination of syringe plungers during the sampling of cyclophosphamide solutions. J Oncol Pharm Practice. 2005; 11:1-5.
• Federica DB, Santoro V, Scarpino V, Martano C, Aigotti R, Chiappa A, Davoli E and Medana C. Antineoplastic drugs determination by HPLC-HRMSn to monitor occupational exposure. Drug Test Anal. 2016; 8:730-737.
• Fent K and Mueller C. Pharmaceutical dust exposure at pharmacies using automatic dispensing machines: a preliminary study. J Occup Environ Hyg. 2014 (Epub ahead of printing) DOI: 10.1080/15459624.2014.918983.
• Ferk F, Misík M, Grummt T, Majer B, Fuerhacker M, Buchmann C, Vital M, Uhl M, Lenz K, Grillitsch B, Parzefall W, Nersesyan A and Knasmüller S. Genotoxic effects of wastewater from an oncological ward. Mutat Res. 2008; 672:69-75.
• Ferrando-Climent L, Rodriguez-Mozaz S and Barceló D. Development of a UPLC-MS/MS method for the determination of ten anticancer drugs in hospital and urban wastewaters, and its application for the screening of human metabolites assisted by information-dependent acquisition tool (IDA) in sewage samples. Anal Bioanal Chem. 2013; 405:5937–5952.
• Fleury-Souverain S, Mattiuzzo M, Mehl F, Nussbaumer S, Bouchoud L, Falaschi L, Gex-Fabry M, Rudaz S, Sadeghipour F and Bonnabry P. Evaluation of chemical contamination of surfaces during the preparation of chemotherapies in 24 hospital pharmacies. Eur J Hosp Pharm. 2015; 22:333-341.
• Fleury-Souverain S, Nussbaumer S, Mattiuzzo M and Bonnabry P. Determination of the external contamination and cross-contamination by cytotoxic drugs on the surfaces of vials available on the Swiss market. J Onc Pharm Practice. 2014; 20:100-111.
• Fleury-Souverain S, Nussbaumer S, Mattiuzzo M, Bonnabry P. Determination of the external contamination and cross-contamination by cytotoxic drugs on the surfaces of vials available on the Swiss market. J Oncol Pharm Practice. 2014; 20:100-111.
• Floridia L, Pietropaolo AM, Tavazzani M, Rubino FM, Colombi A. High-performance liquid chromatography of methotrexate for environmental monitoring of surface contamination in hospital departments and assessment of occupational exposure. J Chromatog B. 1999; 726:95-103.
• Fransman W, Vermeulen R and Kromhout H. Occupational dermal exposure to cyclophosphamide in Dutch hospitals: A pilot study. Ann Occup Hyg. 2004; 48:237-244.
• Fransman W, Vermeulen R and Kromhout H. Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities. Int Arch Occup Health. 2005; 78:403-412.
• Fransman W, Huizer D and Tuerk J. Inhalation and dermal exposure to eight antineoplastic drugs in an industrial laundry facility. Int Arch Occup Environ Health. 2007; 80:396-403.
• Garcia SV, Clérigues NV, Ferrer VF and Briz EL. Use and handling of Mini-Spike 2® chemo and puresite for safe chemotherapy compounding in a hospital pharmacy. Reg Toxicol Pharm 2018; 100:1-6.
• Gilbar PJ. External contamination of cytotoxic drug vials. J Pharm Pract Res. 2005; 35:264-265.
• Gilles L, Favier B, Lombard I, Ardiet C, Boufercha R, Catros F, Eppling I, Fourmaintraux D, Gondran C, Merle JL Pelletier A, Roussel A and Latour JF. Medicaments cytotoxiques: evaluation de l’impact de la purge des lignes de perfusion sur l’exposition du personnel infirmier. Arch Mal Prof. 2004; 65:9–17 (French with English abstract).
• Gomez-Canela C, Cortes-Francisco N, Ventura F, Caixach J and Lacorte S. Liquid chromatography coupled to tandem mass spectrometry and high resolution mass spectrometry as analytical tools to characterize multi-class cytostatic compounds. J Chromatogr A. 2013; 1276:78-94.
• Gómez-Canela C, Ventura F, Caixach J and Lacorte S. Occurrence of cytostatic compounds in hospital effluents and wastewaters, determined by liquid chromatography coupled to high-resolution mass spectrometry. Anal Bioanal Chem. 2014; 406:3801–3814.
• Gonzalez R, Massoomi F. Manufacturers’ recommendations for handling spilled hazardous drugs. Am J Health-Syst Pharm. 2010; 67:1985-1986.
• Graeve CU, McGovern PM, Alexander B, Church T, Ryan A and Polovich M. Occupational exposure to antineoplastic agents: an analysis of health care workers and their environments. Workplace Health and Safety. 2016 (e-pub; doi: 10.117712.165079916662660).
• Guerbet M, Goullé JP and Lubrano J. Evaluation of the risk of contamination of surgical personnel by vaporization of oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol. 2007; 33:623-629.
• Hama T, Aoyama T, Shirai T, Higuchi S, Yokokawa T and Sugimoto Y. Environmental contamination due to preparation of cyclophosphamide and exposure to pharmacists to it. Jpn J Pharm Health Care Sci. 2009; 35: 693-700.
• Hama K, Fukushima K, Hirabatake M, Hashida T and Kataoka K. Verification of surface contamination of Japanese cyclophosphamide vials and an example of exposure by handling. J Oncol Pharm Practice. 2011; 18:201-206.
• Hedmer M, Jonsson BAG, Nygren O. Development and validation of methods for environmental monitoring of cyclophosphamide in workplaces. J Environ Monit. 2004; 6:979-984.
• Hedmer M, Georgiadi A, Rämme Bremberg E, Jönsson BAG and Eksborg S. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Ann Occup Hyg. 2005; 49:629-637.
• Hedmer M, Tinnerberg H, Axmon A and Jönsson BAG. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health. 2008; 81:899-911.
• Hepp R and Gentschew G. Untersuchung zur außenkontamination der primärverpackungen von zytostatika. Krankenhauspharmazie. 1988; 1:22-27.
• Hon C-Y, Teschke K, Chua P, Venners S and Nakashima L. Occupational exposure to antineoplastic drugs: Identification of job categories potentially exposed throughout the hospital medication system. Saf Health Work. 2011; 2:273-281.
• Hon CY, Chua PPS, Danyluk Q and Astrakianakis G. Examining factors that influence the effectiveness of cleaning antineoplastic drugs from drug preparation surfaces: a pilot study. J Oncol Pharm Pract. Published online 8 August 2013.
• Hon C-Y, Teschke K, Chu W, Demers P and Venners S. Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals. J Occup Environ Hyg. 2013; 10:374-383.
• Hon CY, Teschke K, Demers PA and Venners S. Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system. Ann Occup Hyg. 2014; 58:761-770.
• Huang YW, Jian L, Zhang MB, Zhou Q, Yan XF, Hua XD, Zhou Y and He JL. An investigation of oxidative DNA damage in pharmacy technicians exposed to antineoplastic drugs in two Chinese hospitals using the urinary 8-OHdG assay. Biomed Environ Sci. 2012; 25:109-116.
• Ikeda K, Yagi Y, Tkegami M, Lu Y, Morimoto K and Kurokawa N. Efforts to ensure safety of hospital pharmacy personnel occupationally exposed to antineoplastic drugs during a preparation task. Hosp Pharm. 2007; 42:209-218.
• Ishiwata S, Taga A, Sano H, Kobayashi M, Nomiyama J, Harada S, Kita A, Takada M and Sugiura R. Evaluation of brilliance and visibility of fluorescence and chemiluminescence solution for training of preparing injections. Yakugaku Zasshi. 2011; 131:1361-1367 (Japanese).
• Jeonimo M, Colombo M, Astrakianakis G and Hon CY. A surface wipe sampling and LC-MS/MS method for the simultaneous detection of six antineoplastic drugs commonly handled by healthcare workers. Anal Bioanal Chem. 2015 (Epub ahead of print). DOI: 10.1007/s00216-015-8868-y.
• Kibby T. A review of surface wipe sampling compared to biologic monitoring for occupational exposure to antineoplastic drugs. J Occup Environ Hyg. 2017; 14:159–174.
• Kleinberg ML and Quinn MJ. Airborne drug levels in a laminar flow hood. Am J Hosp Pharm. 1981; 38:1301-1303.
• Kiffmeyer TK, Götze H-J, Jursch M and Lüders U. Trace enrichment, chromatographic separtation and biodegradation of cytostatic compounds in surface water. Fresenius J Anal Chem. 1998; 361:185-191.
• Kiffmeyer TK, Ing KG and Schoppe G. External contamination of cytotoxic drug packing: Safe handling and cleaning procedures. J Onc Pharm Practice. 2000; 6:13.
• Kiffmeyer TK, Kube C, Opiolka S, Schmidt KG, Schoppe G and Sessink PJM. Vapour pressures, evaporation behavior and airborne concentrations of hazardous drugs: implications for occupational safety. Pharaceutical J. 2002; 268:331-337.
• Kiffmeyer T, Tuerk J, Hahn M, Stuetzer H, Hadtstein C, Heinemann A and Eickmann U. Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies – the MEWIP project. Ann Occup Hyg. 2013; 57:444-455.
• Koller M, Böhlandt A, Haberl C, Nowak D and Schierl R. Environmental and biological monitoring on an oncology ward during a complete working week. Toxicol Letters 2018; 298:158-163.
• Kopp B, Crauste-Manciet S, Guibert A, Mourier W, Guerrauly-Moro M-N, Ferrari S, Jomier J-Y, Brossard D and Schierl R. Environmental and biological monitoring of platinum-containing drugs in two hospital pharmacies using positive air pressure isolators. Ann Occup. Hyg. 2013; 57:374-383.
• Kopp B, Schierl R and Nowak D. Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings. Int Arch Occup Environ Health. 2013; 86:47-55.
• Kromhout H, Hoek F, Uitterhoeve R, Huijbers R, Overmars RF, Anzion R and Vermeulen R. Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann occup Hyg. 2000; 44:551-560.
• Kushnir CL, Fleury AC, Couch J, Hill MC and Spirtos NM. Evaluation of exposures to healthcare personnel from cisplatin during a mock demonstration of intra-operative intraperitoneal chemotherapy administration. Gynecol Oncol. 2013; 130:350-353.
• Labuhn K, Valanis B, Schoeny R, Loveday K and Vollmer WM. Nurses’ and pharmacists exposure to antineoplastic drugs:Findings from industrial hygiene scans and urine mutagenicity tests. Cancer Nursing. 1998; 21:79-89.
• Ladeira C, Viega S, Padua M, Carolino E, Gomes MC and Brito M. Genotoxic assessment in different exposure groups working with antineoplastic agents. Occupational Safety and Hygiene III. Arezes PM, Baptista JS, Barroso MP, Carneiro P, Cordeiro P, Nelson C, Melo RB, Miguel AS and Perestrelo G. London: Taylor and Francis Group. 2015. ISBN 978-1-138-02765-7.
• Larson RR, Khazaeli MB and Dillon HK. Monitoring method for surface contamination caused by selected antineoplastic agents. Am J Health Syst Pharm. 2002; 59 (3): 270-277.
• Larson RR, Khazaeli MB and Dillon HK. Development of an HPLC Method for simultaneous analysis of five antineoplastic agents Appl Occ Env Hyg. 2003; 18:109-119.
• Larson RR, Khazaeli MB and Dillon HK. A new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents. Appl Occ Env Hyg. 2003; 18:120-131.
• Leboucher G, Serratrice F, Bertholle V Thore L and Bost M. Evaluation of platinum contamination of a hazardous drug preparation area in a hospital pharmacy. Bull Cancer. 2002; 89:949-955.
• Ledford A and Wetzel B. Constructing an oncology pharmacy. Pharm Purch Prod. May 2017 14 (5):
• Le LMM, Reitter D, He S, Bonle FT, Launois A, Martinez D, Prognon P and Caudron E. Safety analysis of occupational exposure of healthcare workers to residual contaminations of cytotoxic drugs using FMECA security approach. Sci Total Environ. 599-600 (2017) 1939-1944.
• Lee S-G, Tkaczuk M, Jankewicz G and Ambados F. Surface contamination from cytotoxic chemotherapy following preparation and administration. J Pharm Pract Res. 2007; 37:271-276.
• Mader RM, Rizovski B and Steger GG. On-line solid-phase extraction and determination of paclitaxel in human plasma. J Chromatog B. 2002; 769:357-361.
• Maeda S, Miyawaki K, Matsumoto S, Oishi M, Miwa Y and Kurokawa N. Evaluation of environmental contaminations and occupational exposures involved in preparation of chemotherapeutic drugs. Yakugaku Zasshi. 2010; 130:903-910.
• Mason HJ, Morton J, Garfitt SJ, Iqbal S and Jones K. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Ann occup Hyg. 2003; 47:681-685.
• Mason HJ, Blair S, Sams C, Jones K, Garfitt SJ, Cuschieri MJ and Baxter PJ. Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann Occup Hyg. 2005; 49:603-610.
• Massoomi F and Knolla KL. Identifying hazardous drug residue via wipe analysis. Pharm Purchasing and Products. 2013; July:42-48.
• McDevitt JJ, Lees PSJ and McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993; 35:57-60.
• McDiarmid MA, Egan T, Furio M, Bonacci M and Watts SR. Sampling for airborne fluorouracil in a hospital drug preparation area. Am J Hosp Pharm. 1986; 43:1942-1945.
• Meijster T, Veldhof R and Kromhout H. Inventariserend onderzoek naar gebruik van en blootstelling aan cytostatica buiten het ziekenhuis. 2003 (English abstract).
• Meijster T, Fransman W, Veldhof R and Kromhout H. Exposure to antineoplastic drugs outside the hospital environment. Ann Occup Hyg. 2006; 50:657-664.
• Merger D, Tanguay C, Langlois E, Lefebvre M and Bussieres JF. Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals. Int Arch Occup Environ Health. 2014; 87:307-313.
• Micoli G, Turci R, Arpellini M and Minoia C. Determination of 5-fluorouracil in environmental samples by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatog B. 2001; 750:25-32.
• Minoia C, Turci R, Sottani C, Schiavi A, Perbellini L, Angeleri S, Draicchio F and Apostoli P. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom. 1998; 12: 1485-1493.
• Minoia C, Turci R, Sottani C, Schiavi A, Perbellini L, Angeleri S, Frigerio F, Draicchio F and Apostoli P. Risk assessment concerning hospital personnel participating in the preparation and administration of antineoplastic drugs. [Italian] Giornale Italiano di Medicina del Lavoro ed Ergonomia. 1999; 21:93-107.
• Miyake T, Iwamoto T, Tanimura M and Okuda M. Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. SpringerPlus. 2013; 2:273.
• Müller-Ramírez C, Squibb K and McDiarmid M. Accessible analytical methodology for assessing workplace contamination of antineoplastic drugs in limited-resource oncology health-care settings. J Anal Sci and Technol. 2016; 7:11.
• Müller-Ramírez C, Squibb K and McDiarmid M. Measuring extent of surface contamination produced by the handling of antineoplastic drugs in low-to-middle-income country oncology health care settings. Arch Occup Environ Health. 2017; 72:289-298.
• Naito T, Osawa T, Suzuki N, Goto T, Takada A, Nakamichi H, Onuki Y, Imai K, Nakanishi K and Kawakami J. Comparison of contamination levels on the exterior surfaces of vials containing platinum anticancer drugs in Japan. Biol Pharm Bull. 2012; 35:2043-2049.
• Nussbaumer S, Bonnabry P, Veuthey JL and Fleury-Souverain S. Analysis of anticancer drugs: a review. Talanta. 2011; 85:2265-2289.
• Nussbaumer S, Geiser L, Sadeghipour F, Hochstrasser D, Bonnabry P, Veuthey JL and Fleury-Souverain S. Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces. Anal Bioanal Chem. 2012; 402:2499-2509.
• Nygren O and Lundgren C. Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int Arch Occ Environ Health. 1997; 70:209-214.
• Nygren O, Gustavsson B, Strom L and Friberg A. Cisplatin contamination on the outside of drug vials. Ann occup Hyg. 2002; 46: 555-557.
• Nygren O, Gustavsson B and Eriksson R. A test method for assessment of spill and leakage from drug preparation systems. Ann Occup Hyg. 2005; 49:711-718.
• Nygren O. Wipe samples as a tool for monitoring aerosol deposition in workplaces. J Environ Monit. 2006; 8;49-52.
• Odraska P, Dolezalova L, Piler P, Oravec M and Blaha L. Utilization of the solid sorbent media in monitoring of airborne cyclophosphamide concentrations and the implications for occupational hygiene. J Environ Monit. 2011; 13:1480-1487.
• Odraska P, Dolezalova L, Kuta J, Oravec M, Piler P and Blaha L. Evaluation of the efficacy of additional measures introduced for the protection of healthcare personnel handling antineoplastic drugs. Ann Occup Hyg. 2013; 57:240-250.
• Odraska P, Dolezalova L, Kuta J, Oravec M, Piler P, Synek S and Blaha L. Association of surface contamination by antineoplastic drugs with different working conditions in hospital pharmacies. Arch Environ Occup Health. 2014; 69:148-158.
• Page E, Couch JR and de Perio MA. Evaluation of a multiple sclerosis cluster among nurses in an inpatient oncology ward. J Occup Environ Hyg. 2015; 12:D54-59.
• Panahi D, Azari M, Akbari ME, Zendehdel R, Mirzaei HR, Hatami H and Mehrabi Y. Development of a new method for sampling and monitoring oncology staff exposed to cyclophosphamide drug. Environ Monit Assess. 2016; 188:238-243.
• Pethran A, Hauff K and Hessel H . Biological, cytogenetic and ambient monitoring of exposure to antineoplastic drugs. J Oncol Pharm Practice. 1998; 4:57.
• Pethran A, Schierl R and Schmaus G. Wipe samples of workplaces with cytotoxic drug exposition. Krankenhauspharmazie. 2001; 1:11-15. (English abstract).
• Poupeau C, Tanguay C, Caron NJ and Bussières J-F. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. J Oncol Pharm Pract 2018; 24:9-17.
• Power LA, Sessink PJM, Gesy K and Charbonneau F. Hazardous drug residue on exterior vial surfaces: evaluation of a commercial manufacturing process. Hosp Pharm. 2014; 49:355-362.
• Pretty JR, Connor TH, Spasojevic I, Kurtz KS, McLaurin JL, B’ Hymer C, Debord DG. Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environment. J Oncol Pharm Pract. 2010; 18:23-36.
• Pyy L, Sorsa M and Hakala E. Ambient monitoring of cyclophosphamide in manufacturing and hospitals. Am Ind Hyg Assoc J. 1988; 49: 314-317.
• Ramphal R, Bains T, Vaillancourt R, Osmond MH and Barrowman N. Occupational exposure to Cyclophosphamide in nurses at a single center. J Occup Environ Med. 2014; 56:304-312.
• Ramphal R, Bains T, Goulet G and Vaillancourt R. Occupational exposure to chemotherapy of pharmacy personnel at a single centre. Can J Hosp Pharm. 2015; 68:104-112.
• Redic KA, Fang K, Christen C and Chaffee BW. Surface contamination of hazardous drug pharmacy storage bins and pharmacy distributor shipping containers. J Oncol Pharm Pract 2018; 24:91-97.
• Ros JJW, Simons KA, Verzijl JM, de Bijl GA and Pelders MG. Practical applications of a validated method of analysis for the detection of traces of cyclophosphamide on injection bottles and at oncological outpatient center. Ziekenhuisfarmacie. 1997; 13:168-171.
• Rubino FM, Floridia L, Pietropaolo AM, Tavazzani M and Colombi A. Measurement of surface contamination by certain antineoplastic drugs using high-performance liquid chromatography: Applications in occupational hygiene investigations in hospital environments. Med Lav. 1999; 90: 572-583.
• Sabatini L, Barbieri A, Tosi M and Violante FS. A new high-performance liquid chromatographic/electrospray ionization tandem mass spectrometric method for the simultaneous determination of cyclophosphamide, methotrexate and 5-fluorouracil as markers of surface contamination for occupational exposure monitoring. J Mass Spectrom. 2005; 40:669-674.
• Schierl R, Bohlandt A and Nowak D. Guidance values for surface monitoring of antineoplastic drugs in German pharmacies. Ann Occup Hyg. 2009; 53:1-9.
• Schierl R, Herwig A, Pfaller A, Groebmair and Fischer E. Surface contamination of antineoplastic drug vials: Comparison of unprotected and protected vials. Am J Health-Syst Pharm. 2010; 67:428-429.
• Schierl R, Novotna J, Piso P, Bohlandt A and Nowak D. Low surface contamination by cis/oxaliplatin during hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol. 2012; 38:88-94.
• Schierl R, Masini C, Groeneveld S, Fischer E, Bohlandt A, Rosini V and Paolucci D. Environmental contamination by cyclophosphamide preparation: comparison of conventional manual production in biological safety cabinet and robot-assisted production by APOTECAchemo. J Oncol Pharm Practice. 2016; 22:37-45.
• Schmaus G, Schierl R and Funck S. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am J Health-Syst Pharm. 2002; 59:956-961.
• Schmid K, Boettcher MI, Pelz JOW, Meyer T, Korinth G, Angerer J and Drexler. Investigation on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C. Eur J Surg Oncol. 2006; 32:1222-1225.
• Schulz H, Bigelow S, Dobish R and Chambers CR. Antineoplastic agent workplace contamination study: the Alberta Cancer Board Pharmacy perspective. J Oncol Pharm Pract. 2005; 11:101-109.
• Sessink PJM, Anzion RB, Van den Broek PHH and Bos RP. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl (Sci). 1992; 14:16-22.
• Sessink PJM, Joost HC, Pierik FH, Anzion RBM and Bos RP. Occupational exposure of animal caretakers to cyclophosphamide. J Occup Med. 1993; 35:47-52.
• Sessink PJM, Friemèl NSS, Anzion RBM and Bos RP. Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int Arch Occup Environ Health. 1994; 65:401-403.
• Sessink PJM, Wittenhorst BCJ, Anzion RBM and Rob RP. Exposure of pharmacy technicians to antineoplastic agents: Reevaluation after additional protective measures. Arch Environ Health. 1997; 52:240-244.
• Sessink PJM, Rolf M-AE and Rydèn NS. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm. 1999; 34:1311-1317.
• Sessink PJM, Connor TH, Jorgenson JA and Tyler TG. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Practice. 2011; 17:39-48.
• Sessink PJM, Leclercq GM, Wouters DM, Halbardier L, Hammad C and Kassoul N. Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation. J Oncol Pharm Practice. 2015; 21
• Shahsavarani S, Godefroid RJ and Harrison BR. Evaluation of occupational exposure to tablet trituration dust. ASHP Midyear Clinical Meeting. 1993; P-59(E) abs.
• Siderov J, Kirsa S and McLauchlan R. Surface contamination of cytotoxic chemotherapy preparation areas in Australian hospital pharmacy departments. J Pharm Pract Res. 2009; 39: 117-121.
• Siderov J, Kirsa S and McLauchlan R. Surface contamination of cytotoxic chemotherapy preparation areas in Australian hospital pharmacy departments. J Pharm Pract Res. 2009; 39: 117-121.
• Siderov J, Kirsa S and McLauchlan R. External surface contamination of cytotoxic admixtures” Caveat Emptor. J Pharm Pract Res. 2011; 41:181-182.
• Simon N, Vasseur M, Pinturaud M, Soichot M, Richeval C, Humbert L, Lebecque M, Sidikou O, Barthelemy C, Bonnabry P, Allorge D, Décaudin B and Odou P. Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug compounding unit: a prospective, controlled, parallel study. PLOS ONE. 2016; 11:e0159052.
• Smith JP, Sammons DL, Robertson SA, Pretty JR, DeBord DG, Connor TH and Snawder JE. Detection and measurement of surface contamination by multiple antineoplastic drugs using multiplex bead assay. J Oncol Pharm Practice. 2016; 22:60-67.
• Smith JP, Sammons DL, Pretty JR, Kurtz KS, Robertson SA, DeBord DG, Connor TH and Snawder JE. Detection of 5-fluorouracil surface contamination in near real time. J Oncol Pharm Pract. 2016; 22:396-408.
• Smith, ST and Szlaczky MC. Syringe plunger contamination by hazardous drugs: a comparative study. J Oncol Pharm Practice. 2014 (Epub ahead of print) DOI: 10.1177/1078155214526428.
• Snell J, Lillquist DR, Lewis-Younger C and Wallace DO. Exposure at home to airborne concentrations of nitrogen mustard during topical application for treatment of mycosis fungoides: a case study. Dermatology. 2000; 200:124-128.
• Solaβ W, Giger-Pabst U, Zieren J and Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol. 2013; 20:3504-3511.
• Sorsa M, Pyy L, Salomaa S, Nyland L and Yager JW. Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mutat Res. 1988; 204:465-479.
• Sottani C, Turci R, Micoli G, Fiorention ML and Minoia C. Rapid and sensitive determination of paclitaxel (Taxol) in environmental samples by high-performance liquid chromatography tandem mass spectrometry. Rapid Comm Mass Spectrom. 2000; 14:930-935.
• Sottani C, Truci R, Schierl R, Gaggeri R, Barbieri A, Violante FS and Minoia C. Simultaneous determination of gemcitabine, taxol, cyclophosphamide and ifosphamide in wipe sampels by high-performance liquid chromatography/tandem mass spectrometry: protocol of validation and uncertainty of measurment. Rapid Commun Mass Spectrom. 2007; 21:1289:1296.
• Sottani C, Porro B, Cornelli M, Imbriani M and Minoia C. An analysis to study trends in occupational exposure to antineoplastic drugs among health care workers. J Chromatog B. 2010; 878:2593-2605.
• Sottani C, Porro B, Imbriani M and Minoia C. Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicol Lett. 2012; 213:107-115.
• Stover D and Achutan C. Occupational exposures to antineoplastic drugs in an oncology-hematology department. J Occup Environ Hyg. 2011; 8: D1-D6.
• Stuart A, Stephens AD, Welch L and Sugarbaker PH. Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. Ann Surg Oncol. 2002; 9:186-191.
• Sugiura S, Asano M, Kinoshita K, Tanimura M and Nabeshima T. Risks to health professionals from hazardous drugs in Japan: a pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide. J Oncol Pharm Practice. 2010; 17:14-19.
• Suguira S, Nakanishi H, Asano M, Hashida T, Tanimura M, Hama T and Nabeshima T. Multicenter study for environmental and biological monitoring of occupational exposure to cyclophosphamide in Japan. J Oncol Pharm Practice. 2010; 17:20-28.
• Tanimura M, Yamada K, Sugiura S, Mori K, Nagata H, Tadokoro K, Miyake T, Hamaguchi Y, Sessink P, Nabeshima T. An environmental and biological study of occupational exposure to cyclophosphamide in the pharmacy of a Japanese community hospital designated for the treatment of cancer. J Health Sci. 2009; 55: 750-756.
• Tkaczuk M, Lee SG, Jankewicz G and Ambados F. Surface contamination of cytotoxic drug 5-Fluorouracil (5-FU) and decontamination. AIOH Conference. 2009. (abs)
• Touzin K, Bussières JF, Langlois É, Lefebvre M and Gallant C. Cyclophosphamide contamination observed on the surface of drug vials and the efficacy of cleaning on vial contamination. Ann Occup Hyg. 2008; 1-7.
• Touzin K, Bussières JF and Langlois É. Evaluation of surface contamination in a hospital hematology-oncology pharmacy. J Oncol Pharm Practice. 2009; 15: 53-61.
• Tuerk J, Reinders M, Dryer M, Kiffmeyer TK, Schmidt KG and Kuss HM. Analysis of antibiotics in urine and wipe samples from environmental and biological monitoring- comparison of HPLC with UV-, single MS- and tandem MS-detection. J Chromatog. 2006; 831:72-80.
• Tuerk J, Kiffmeyer TK, Hadtstein C, Heinemann A, Hahn M, Stuetzer H, Kuss HM and Eickmann U. Development and validation of an LC-MS/MS procedure for environmental monitoring of eight cytostatic drugs in pharmacies. Intern J Environ Anal Chem. 2011; 91:1178-1190.
• Turci R, Micoli G and Minoia C. Determination of methotrexate in environmental samples by solid phase extraction and high performance liquid chromatorgraphy: ultraviolet or tandem mass spectrometry detection. Rapid Comm Mass Spectrom. 2000; 14:685-691.
• Turci R, Sottani C, Spagnoli G and Minoia C. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J Chromatog B. 2003; 789:169-209.
• Turci R and Minoia C. Residual hazard assessment related to handling of antineoplastic drugs: safety system evolution and quality assurance of analytical measurement. Ann NY Acad Sci. 2006; 1076:649-656.
• Turci R, Minola C, Sottani C, Coghi R, Severi P, Castriotta C, Del Bianco M and Imbriani M. Occupational exposure to antineoplastic drugs in seven Italian hospitals: the effect of quality assurance ad adherence to guidelines. J Oncol Pharm Practice. 2011; 17:320-332.
• Ursini CL, Cavallo D, Colombi A, Giglio M, Marinaccio A and Iavicoli S. Evaluation of early DNA damage in healthcare workers handeling antineoplastic drugs. Int Arch Occup Environ Health. 2006; 80:134-140.
• Valanis B. Environmental and direct measures of exposure. Occup Med. 1986; 1:431-444.
• Vazquez R, Boubet K, Guerrault-Moro MN and Crauste-Manciet S. Impact of handling errors for chemical cross-contamination risk for the preparation of parenteral cytotoxic drugs. Pharm Technol Hosp Pharm. 2016;1:115-122.
• Viegas S, Padua M, Veiga AC, Carolino E and Gomes M. Antineoplastic drugs contamination of workplace surfaces in two Portuguese hospitals. Environ Monit Assess. 2014; 186:7807-7818.
• Villa AF, El Balkhi S, Aboura R, Sageot H, Hasni-Pichard H, Pocard M, Elias D, Joly N, Payen D, Blot F, Poupon J and Garnier R. Evaluation of oxaliplatin exposures of healthcare workers during heated intraperitoneal perioperative chemotherapy (HIPEC). Ind Health. 2015; 53:28-37.
• Villarini M, Dominici L, Piccinini R, Fatigoni C, Ambrogi M, Curti G, Morucci P, Muzi G, Monarca S and Moretti M. Assessment of primary, oxidative and excision repaired DNA damage in hospital personnel handling antineoplastic drugs. Mutagenesis. November 2010; 1-11.
• Wakui N, Ookubo T, Iwasaki Y, Ito R, Mitui M, Yano Y, Saito K and Nakazawa H. Determination of exposure of dispensary drug prepares to cyclophosphamide by passive sampling and liquid chromatography with tandem mass spectrometry. J Oncol Pharm Practice. 2012; 19:31-37.
• Wick C, Slawson MH, Jorgenson JA and Tyler LS. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health-Syst Pharm. 2003; 60:2314-2320.
• Wilken A. Beobachtungen zur Außenkotamination der primärverpackungen von zytostatika. Krakenhauspharmazie. 1997; 1:37-39.
• Yabunaka H, Sakaguchi F, Kobayashi Y and Nakanishi H. Investigation on vaporization of solution of Endoxan®. Jpn J Pharm Health Care Sci. 2010; 36:343- 346.
• Yoshida J, Kosaka H, Tomika K and Kumagai S. Genotoxic Risks to nurses from contamination of the work enviroment with antineoplastic drugs in Japan. J Occup Health; 2006; 48:517-522.
• Yoshida J, Kosaka H, Tomioka K and Kumagai S. Genotoxic risks to nurses from contamination of the work environment with antineoplastic drugs in Japan. J Occup Health. 2006; 48:517-522.
• Yoshida J, Koda S, Nishida S, Yoshida T, Miyajima K and Kumagai S. Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. J Oncol Pharm Practice. 2010; 17:29-38.
• Yoshida J, Koda S, Nishida S, Nakano H, Tei G and Kumagai S. Association between occupational exposure and control measures for antineoplastic drugs in a pharmacy of a hospital. Ann Occup Hyg. 2013; 57:251-260.
• Yuki M, Sekine S, Takase K, Ishida T and Sessink PJM. Exposure of family members to antineoplastic drugs via excreta of treated cancer patients. J Oncol Pharm Pract. 2012; 19:208-217.
• Yuki M, Takase K, Sekine S and Ishida T. Evaluation of surface contamination with cyclophosphamide in the home setting of outpatients on cancer chemotherapy. J Nurs Educ Prac. 2014; 4:16-23.
• Zeedijk M, Greijdanus B, Steenstra FB and Uges DRA. Monitoring exposure of cytotoxics on the hospital ward: measuring surface contamination of four different cytotoxic drugs from one wipe sample. Eur J Hosp Pharm. 2005; 1:18-22.
• Ziegler E, Mason HJ and Baxter PJ. Occupational exposure to cytotoxic drugs in two UK oncology wards. Occup Environ Med. 2002; 59:608-612.

Several reports have dealt with methods for the decontamination and/or deactivation of antineoplastic agents. Although bleach (hypochlorite) is often recommended for the decontamination purposes, it is not effective with all classes of agents. Therefore, it cannot be assumed that cleaning with bleach solutions will destroy all types of antineoplastic agents. Some antineoplastic drugs are listed by the US Environmental Protection Agency as Hazardous waste and must be disposed of accordingly (see 40 CFR 261.33).

• AIHA Healthcare Working Group Hazardous Drugs Project Team. Chemotherapy hood decommissioning for disposal or recycling. Fact sheet. Approved by AIHA Board: October 17, 2016. Falls Church, VA: American Industrial Hygiene Association (AIHA).
• Anastasi M, Rudaz S, Lamerie TQ, Odou P, Bonnabry P and Fleury-Souverain S. Efficacy of two cleaning solutions for the decontamination of 10 antineoplastic agents in the biosafety cabinets of a hospital pharmacy. Ann Occup Hyg. 2015; 59:895-908.
• Barek J, Cvaccka J, Zima J, De Meo M, Laget M, Michelon J and Castegnaro M. Chemical degradation of wastes of antineoplastic agents amsacrine, azathioprine, asparaginase and thiotepa. Ann Occup Hyg. 1998; 42:259-266.
• Bassi MD and Moretton J. Mutagenicity of antineoplastic drug residues treated in health care waste autoclave. Bull Environ Contam Toxicol. 2003; 71:170-175.
• Benvenuto JA, Connor TH, Monteith DK, Laidlaw JA, Adams SC, Matney TS and Theiss JC. Degradation and inactivation of antitumor drugs. J Pharm Sci. 1993; 82:988-991.
• Bohlandt A, Groeneveld S, Fischer E and Schierl R. Cleaning Efficiencies of three cleaning agents on four different surfaces after contamination by Gemcitabine and 5-fluorouracile. J Occup Environ Hyg. 2015; 12:384-392.
• Castegnaro M, De Meo M, Laget M, Michelon J, Garren L, Sportouch MH and Hansel S. Chemical degradation of wastes of antineoplastic agents 2: Six anthracyclines: idarubicin,doxorubicin, epirubicin, pirarubicin, aclarubicin, and daunorubicin. Int Arch Occup Environ Health. 1997; 70:378-384.
• Chu WC, Hon C-Y, Danyluk Q, Chua PPS and Astrakianakis G. Pilot assessment of the antineoplastic drug contamination levels in British Columbia hospitals pre- and post-cleaning. J Oncol Pharm Practice. (Published on line 2011; DOI: 10.1177/1078155211402106).
• Cox J, Speed V, O’Neal S, Hasselwander T, Sherwood C, Eckel SF and Zamboni WC. Development and evaluation of a novel product to remove surface contamination of hazardous drugs. J Oncol Pharm Pract. 2017; 23:103-115.
• Gohma H, Inoue Y, Asano M and Sugiura SI. Testing the degradation effects of three reagents on various antineoplastic compounds. J Oncol Pharm Practice. 2014; (Epub ahead of print) DOI: 10.1177/1078155214530175.
• Hansel S, Castegnaro M, Sportouch MH, De Meo M, Milhavet JC, Laget M and Dumenil G. Chemical degradation of wastes of antineoplastic agents: cyclophosphamide, ifosfamide and melphalan. Int Arch Occup Environ Health. 1997; 69:109-114.
• Hon CY, Chua PPS, Danyluk Q and Astrakianakis G. Examining factors that influence the effectiveness of cleaning antineoplastic drugs from drug preparation surfaces: a pilot study. J Oncol Pharm Pract. Published online 8 August 2013.
• Hon CY, Chua PPS, Danyluk Q and Astrakianakis G. Examining factors that influence the effectiveness of cleaning antineoplastic drugs from drug preparation surfaces: a pilot study. J Oncol Pharm Practice. 2014; 20:210-216.
• Lamerie TQ, Nussbaumer, S, Décaudin B, Fleury-Souverain S, Goosens J-F, Bonnabry P and Odou P. Evaluation of decontamination efficiency of cleaning solutions on stainless steel and glass surfaces contaminated by 10 antineoplastic agents. Ann Occup Hyg. 2013; 57:456-469.
• Lé LMM, Jolivot PA, Yaye HS, Rieutord A, Bellanger A, Pradeau D, Barbault-Foucher S and Caudron E. Effectiveness of cleaning of workplace cytotoxic surface. Int Arch Occup Environ Health. 2013; 86:333-341.
• Lee S-G, Ambados F Tkaczuk M andJankewicz G. Paclitaxel exposure and its effective decontamination. J Pharm Pract Res. 2009; 39:181-185.
• Lunn G and Sansone EB. Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid. Am J Hosp Pharm. 1987; 44:2519-2524.
• Lunn G, Sansone EB, Andrews AW and Hellwig LC. Degradation and disposal of some antineoplastic drugs. J Pharm Sci. 1989; 78:652-659.
• Roberts S, Khammo N, McDonnell and Sewell GJ. Studies on the decontamination of surfaces exposed to cytotoxic drugs in chemotherapy workstations. J Oncol Pharm Practice. 2006; 12:95-104.
• Smith CA. Managing pharmaceutical Waste-What pharmacists should know. J Phram Soc Wisconsin. 2002; Nov/Dec: 17-22.
• Touzin K, Bussières JF, Langlois É, Lefebvre M and Gallant C. Cyclophosphamide contamination observed on the surface of drug vials and the efficacy of cleaning on vial contamination. Ann Occup Hyg. 2008; 1-7.
• Touzin K, Bussières JF, Langlois É, Lefebvre M and Métra A. Pilot study comparing the efficacy of two cleaning techniques in reducing environmental contamination with cyclophosphamide. Ann Occup Hyg. 2010; 54:351-359.
• Wren AE, Melia CD, Garner ST and Denyer SP. Decontamination methods for cytotoxic drugs. 1. Use of a bioluminescent technique to monitor the inactivation of methotrexate with chlorine-based agents. J Clin Pharm and Therap. 1993; 18:133-137.

The most often used type of protective equipment for handling antineoplastic agents is gloves. Typically latex and other materials have been employed for this use. However, with the concern over latex allergies, newer materials are being marketed and evaluated for use with these agents. Protective gowns are another piece of equipment that is commonly used in the handling of antineoplastic agents. This section also deals with biological safety cabinets and closed system devices used in the preparation of antineoplastic drugs.

• Alexander K, Northrup N, Clarke D, Lindell H and Laver T. Engineering controls in veterinary oncology: a survey of 148 ACVIM board-certified oncologists and environmental surveillance in 20 specialty hospitals. Vet Comp Oncol 2018; 16:385-391.
• Benoit L, Cheynel N, Ortega-Deballon P, Di Giacomo G, Chauffert B, Rat P. Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol. 2007; 15:542-546.
• Boccellino M, Pedata P, Castiglia L, La Porta R, Pieri M, Quagliuolo L, Acampora A, Sannolo N and Miraglia N. Doxorubicin can penetrate nitrile gloves and induces apoptosis in keratinocytes cell lines. Toxicol Lett. 2010; 197:61-68.
• Capron A, Destree J, Jacobs P and Wallemacq P. Permeability of gloves to selected chemotherapeutic agents after treatment with alcohol or isopropyl alcohol. Am J Health- Syst Pharm. 2012; 69:1665-1670.
• Cazin J-L and Gosselin P. Implementing a multiple-isolator unit for centralized preparation of cytotoxic drugs in a cancer center pharmacy. Pharm World Sci. 1999; 21:177-183.
• Colligan SA and Horstman SW. Permeation of cancer chemotherapeutic drugs through glove materials under static and flexed conditions. Appl Occ Environ Hyg. 1990; 5:848-852.
• Connor TH, Laidlaw JL, Theiss JC Anderson RW and Matney TS. Permeability of latex and polyvinyl chloride gloves to carmustine. Am J Hosp Pharm. 1984; 41:676-679.
• Connor TH. An evaluation of the permeability of disposable poylpropylene-based protective gowns to a battery of cancer chemotherapy drugs. Appl Occup Environ Hyg. 1993;8:785-789.
• Connor TH. Permeability testing of glove materials for use with cancer chemotherapy drugs. Oncology. 1995; 52:256-259.
• Connor TH. Permeability of nitrile rubber, latex, polyurethane, and neoprene gloves to 18 antineoplastic drugs. Am J Health-Syst Pharm. 1999; 56: 2450-53.
• Connor TH and Xiang Q. The effect of isopropyl alcohol on the permeation of gloves exposed to antineoplastic agents. J Oncol Pharm Practice. 2000; 6: 109-114.
• Connor TH. Using PPE to prevent occupational exposure to antineoplastic and other hazardous drugs. Pharm Purchasing & Products. 2006; 2:4-6.
• Connor TH. Personal protective equipment for use in handling hazardous drugs. Pharm Purchasing & Products. 2006; 3:2-6.
• Connor, TH, Power LA, Massoomi F and Polovich M. White glove test for safety. ECNews. 2015; 18: 6-7, 11.
• Connor TH, Power LA, Massoomi F and Polovich M. Are gloves and gowns safe for handling chemotherapy? Pharm Purchasing and Products. 2015; 12:2,4.
• Dinter-Heidorn H and Carstens G. Comparative study on protective gloves for handling cytotoxic medications: A model study with carmustine. Pharmaceutisch Weekblad Sci. 1992; 14:180-184.
• Dolezalova L, Odraska P, Gorna L, Prudilova M, Vejpustkova R and Blaha L. Evaporation of selected cytotoxic drugs and permeation of protective gloves – research into the occupational risks of health care personnel handling hazardous cytotoxic drugs (CYTO project). Klin Onkol. 2009; 22(5):218-222.
• Donner AL. Possible risk of working with antineoplastic drugs in horizontal laminar flow hoods (letter). Am J Hosp Pharm. 1978; 35:900.
• Douglas K, Richter A, Dorey M and Rizvi I. Refining PPE usage for HD compounding: Part 1. Pharm Pract Prod. 2017; February 2017 14 (2):18-21.
• Furlow B. How to improve the safety of chemotherapy administration. Oncology Nurse Advisor. 2010; 21-25.
• Georgiad A, Ramme E, Wretman C and Eksborg S. How to create acceptable working conditions for hospital pharmacy staff when preparing cytotoxic drugs. Euro J Hosp Pharm. 2004; 3: 40-42.
• Graeve C, McGovern PM, Arnold S and Polovich M. Testing an intervention to decrease healthcare workers’ exposure to antineoplastic agents. ONF 2017; 44(1):E10–E19
• Graeve CU, McGovern PM, Alexander B, Church T, Ryan A and Polovich M. Occupational exposure to antineoplastic agents: an analysis of health care workers and their environments. Workplace Health and Safety. 2016 (e-pub; doi: 10.117712.165079916662660).
• Gross ER and Groce DF. An evaluation of nitrile gloves as an alternative to natural rubber latex for handling chemotherapeutic agents. J Oncol Pharm Practice. 1998; 4:165-168.
• He BY, Mendelsohn-Victor K, Mccullagh MC and Friese CR. Personal protective equipment use and hazardous drug spills among ambulatory oncology nurses. ONF 2017; 44: 60–65.
• Hennessy KA and Dynan J. Improving compliance with personal protective equipment use through the model for improvement and staff champions. Clin J Oncol Nurs. 2014; 18:497-500.
• Klein M, Rau S, Samev N and Carstens G. Protection offered by selected medical gloves made of either latex or a synthetic elastomer against exposure to nine cytotoxic agents. European Hosp Pharm. 1999; 5:152-158.
• Klein M, Lambov N, Samev N and Carstens G. Permeation of cytotoxic formulations through swatches from selected medical gloves. Am J Health-Syst Pharm. 2003; 1006-1011.
• Korinth G, Schmidt K., Midasch O, Boettcher M I, Angerer J and Drexler H. Investigations on permeation of mitomycin C through double layers of natural rubber gloves. Ann Occup Hyg. 2007; 51:593-600.
• Krämer I, Federici M. Kaiser V and Thiesen J. Media-fill simulation tests in manual and robotic aseptic preparation of injection solutions in syringes. J Oncol Pharm Pract. 2014 (epub. DOI: 10.1177/1078155214565123).
• Labella CJ. Does your pharmacy have a compounding isolator? Am J Health-Syst Pharm. 2007; 64:855-858.
• Lalande L, Galy G, Dussossoy E, Noyel JE and Pivot C. Evaluation of safe infusion devices for antineoplastic administration. J Infus Nurs. 2012; 35:321-327.
• Laidlaw JL, Connor TH, Theiss JC Anderson RW and Matney TS . Permeability of latex and polyvinyl gloves to 20 antineoplastic drugs. Am J Hosp Pharm. 1984; 41:2618-2623.
• Laidlaw JL, Connor TH, Theiss JC, Anderson RW and Matney TS. Permeability of four disposable protective-clothing materials to seven antineoplastic drugs. Am J Hosp Pharm. 1985; 42:2449-2454.
• Landeck L, Gonzalez E and Koch OM. Handling chemotherapy drugs – do medical gloves really protect? Int J Cancer. 2014; (Epub ahead of print) DOI: 10.1002/ijc.29058.
• Lecordier J, Plivard C, Gardeux M, Daouadi K and Lehet J-J. To create a cleanroom controlled environement using a mobile air decontamination unit for the preparation of antineoplastic drugs. J Oncol Pharm Pract. 2014. (epub. DOI: 10.1177/1078155214565125)
• Ledford A and Wetzel B. Constructing an oncology pharmacy. Pharm Purch Prod. May 2017; 14 (5):10-15.
• Mader RM, Rizovski B, Steger GG Moser K, Rainer H and Dittrich C. Permeability of latex membranes to anti-cancer drugs. Int J Pharmaceut. 1991; 68:151-156.
• Mellström GA, Wrangsjö K, Wahlberg JE and Fryklund B. The value and limitations of protective gloves in medical health service:Part I. Dermatol Nurs. 1996; 8:160-164.
• Mellström GA, Wrangsjö K, Wahlberg JE and Fryklund B. The value and limitations of protective gloves in medical health service:Part II. Dermatol Nurs. 1996; 8:287-295.
• Mellström GA, Wrangsjö K, Wahlberg JE and Fryklund B. The value and limitations of protective gloves in medical health service:Part III. Dermatol Nurs. 1996; 8:345-355.
• Nygren O. Wipe samples as a tool for monitoring aerosol deposition in workplaces. J Environ Monit. 2006; 8;49-52.
• Odraska P, Dolezalova L, Kuta J, Oravec M, Piler P and Blaha L. Evaluation of the efficacy of additional measures introduced for the protection of healthcare personnel handling antineoplastic drugs. Ann Occup Hyg. 2012; August 27 (Epub ahead of printing) DOI:10.1093/annhyg/mes057.
• Peters GF, McKeon MK and Weiss WT. Potential for airborne contamination in turbulent- and unidirectional-airflow compounding aseptic isolators. Am J Health-Syst Pharm. 2007; 64:622-631.
• Sewell GJ. The use of isolators for cytotoxic drug handling in hospital pharmacies. Eur J Parent Soi. 1999; 4:55-59.
• Singleton L and Connor, TH. An evaluation of the permeability of chemotherapy gloves to three cancer chemotherapy drugs. Onc Nurs Forum. 1999; 26:1491-1496.
• Slevin ML, Ang LM, Johnston A and Turner P. The efficiency of protective gloves used in the handling of cytotoxic drugs. Cancer Chemother Pharmacol. 1984; 12:151-53.
• Stajich GV, Barnett CW, Turner SV and Henderson CA. Protective measures used by oncologic office nurses handling parenteral antineoplastic agents. Oncol Nurs Forum. 1986; 13:47-49.
• Stoikes ME, Carlson JD, Farris FF and Walker PR. Permeability of latex and polyvinyl chloride gloves to fluorouracil and methotrexate. Am J Hosp Pharm. 1987; 44:1341-1346.
• Thomas PH and Fenton-May V. Protection offered by various gloves to carmustine exposure. The Pharm J. 1987; 238:775-777.
• Thomsen K and Mikklesen HI. Protective capacity of gloves used for handling nitrogen mustard. Contact Derm. 1975; 1:268-269.
• Tomas ME, Kundrapu S, Thota P, Sunkesula VCK, Cadnum JL, Mana TSC, Jencson A, O’Donnell M, Zabarsky TF, Hecker MT, Ray AJ, Wilson BM and Donskey CJ. Contamination of health care personnel during removal of personal protective equipment. JAMA Intern Med. 2015 (Epub ahead of print). DOI: 10.1001/jamainternmed.2015.4535.
• Tompa A, Jakab M, Biro A, Magyar B, Fodor Z, Klupp T and Major J. Chemical safety and health conditions among Hungarian hospital nurses. Ann NY Acad Sci. 2006; 1076:635-648.
• Villa AF, El Balkhi S, Aboura R, Sageot H, Hasni-Pichard H, Pocard M, Elias D, Joly N, Payen D, Blot F, Poupon J and Garnier R. Evaluation of oxaliplatin exposures of healthcare workers during heated intraperitoneal perioperative chemotherapy (HIPEC). Ind Health. 2015; 53:28-37.
• Vyas N, Yiannakis D, Turner A and Sewell GJ. Occupational exposure to anti-cancer drugs: A review of effects of new technology. J Oncol Pharm Pract. 2014; 20:278-287.
• Wagner JT. Ensure safe use of CAIs and CACIs. Pharm Purchasing and Products. 2014; 11 (12):12,14.
• Wagner JT. Considerations for choosing a primary engineering control for compounding sterile products. Int J Pharm Comp. 2005; 9:284-290.
• Wallemacq PE, Capron A, Vanbinst R, Boeckmans E, Gillard J and Favier B. Permeability of 13 different gloves to 13 cytotoxic agents under controlled dynamic conditions. Am J Health-Syst Pharm. 2006; 63:547-556.

• Chen WH, Shen LJ, Guan RJ and Wu FL. Assessment of an automatic robotic arm for dispensing of chemotherapy in a 2500-bed medical center. J Formos Med Assoc. 2013; 112:193-200.
• Krämer I, Federici M, Kaiser V and Thiesen J. Media-fill simulation tests in manual and robotic aseptic preparation of injection solutions in syringes. J Oncol Pharm Practice. 2014 (Epub ahead of print). DOI: 10.1177/1078155214565123.
• Masini C, Nanni O, Antaridi S, Gallegati D, Marri M, Paolucci D, Minguzzi M and Altini M. Automated preparation of chemotherapy: quality improvement and economic sustainability. Am J Health-Sys Pharm. 2014; 71:579-585.
• McLeod M, Zochowska A, Leonard D, Crow M, Jacklin A, Franklin BD. Comparing the upper limb disorder risks associated with manual and automated cytotoxic compounding: a pilot study. Eur J Hos Pharm. 2012; 19:293-298.
• Nurgat Z, Faris D, Mominah M, Vibar A, AL-Jazairi A, Ewing S, Ashour M, Qaisi SK, Balhareth S and AL-Jedai A. A three-year study of a first-generation chemotherapy-compounding robot. Am J Health-Syst Pharm. 2015; 72:1036-1045.
• Palma E and Bufarini C. Robotized compounding of oncology drugs in a hospital pharmacy. Int J Pharm Compd. 2014; 18:358-364.
• Schierl R, Masini C, Groeneveld S, Fischer E, Bohlandt A, Rosini V and Paolucci D. Environmental contamination by cyclophosphamide preparation: comparison of conventional manual production in biological safety cabinet and robot-assisted production by APOTECAchemo. J Oncol Pharm Practice. 2016; 22:37-45.
• Seger AC, Churchill WW, Keohane CA, Belisle CD, Wong ST, Sylvester KW, Chesnick MA, Burdick E, Wien MF, Cotugno MC, Bates DW and Rothschild JM. Impact of robotic antineoplastic preparation on safety, workflow, and costs. J Oncol Pract. 2012; Nov 1:344-350.
• Sessink PJM, Leclercq GM, Wouters DM, Halbardier L, Hammad C and Kassoul N. Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation. J Oncol Pharm Practice. 2014; (Epub ahead of print) DOI: 10.1177/1078155214522840.
• Yaniv AW and Knoer SJ. Implementation of an i.v.-compounding robot in a hospital-based cancer center pharmacy. Am J Health-Syst Pharm. 2013; 70:2030-2037.

NIOSH defines a closed system drug transfer device as: “A drug transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system.” There are several CDTDs currently available from different manufacturers. CSTDs have been shown to reduce the levels of surface contamination present where antineoplastic drugs are handled and to reduce the percentage of wipe samples that have detectable amounts of antineoplastic drugs.

• Bartel SB, Tyler TG and Power LA. Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs. Am J Health Syst Pharm 2018; 75:199-211.
• Berdi F, Powell MF, Sanz C, Gonzalez R and Massoomi F. Assessing the efficiency of CSTDs for compounding. Pharm Purch Products. 2015; 12:4-7.
• Berdi F, Powell M, Sanz C, Gonzalez R and Massoomi F. Assessing the efficiency of CSTDs for compounding. Pharm Purch Prod. July 2015; 12 (7) Supp.
• Connor TH, Anderson RW, Sessink PJ and Spivey SM. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health-Syst Pharm. 2002; 59:68-72.
• Clark BA and Sessink PJM. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents. J Oncol Pharm Prac. 2013; 19:99-104.
• De Ausen L, DeFreitas EF, Littleton L and Lustik M. Leakage from closed-system transfer devices as detected by a radioactive tracer. Am J Health-Syst Pharm. 2013; 70:619-623.
• De Prijck K, D’Haese E, Vandenbroucke J, Coucke W, Robays H and Nelis HJ. Microbiological challenge of four protective devices for the reconstitution of cytotoxic agents. Lett Appl Micro. 2008; 47:543-548.
• Edwards MS, Solimando DA, Grollman FR, Pang JL, Chasick AH, Hightman CM, Johnson AD, Mickens MG and Preston LM. Cost savings realized by use of the PhaSeal® closed-system transfer device for preparation of antineoplastic agents. J Oncol Pharm Pract. 2013; 19:338-347.
• Favier B, Labrosse H, Gilles-Afchain L, Cropet C, Perol D, Chaumard N, Latour JF and Hild P. The PhaSeal® system: impact of its use on workplace contamination and duration of chemotherapy preparation. J Oncol Pharm Practice. 2011; 18:37-45.
• Forges F, Simoens X and Chauvin F. Comparative parallel assessment of a transfer device in reducing 5-fluorouracil environmental contamination inside positive air pressure isolators. J Oncol Pharm Practice. 2011; 17:61-67.
• Forshay CM, Streeter SO, Salch SA and Eckel SF. Application of the 2015 proposed NIOSH vapor containment performance protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs. J Oncol Pharm Pract 2018; July, doi: 10.1177/1078155218787256external icon.
• Garcia SV, Clérigues NV, Ferrer VF and Briz EL. Use and handling of Mini-Spike 2® chemo and puresite for safe chemotherapy compounding in a hospital pharmacy. Reg Toxicol Pharm 2018; 100:1-6.
• Garrigue P, Montana M, Ventre C, Gauthier-Villano L, Pisano P and Pourroy B. Safe cytotoxic drug preparation using closed-system transfer device: technical and practical evaluation of a new device (Vialshield/Texium) comparatively to a reference one (Phaseal). Int J Pharm Compounding. 2016; 20:148-154.
• Gomez-Alvarez S, Porta-Oltra B, Hernandez-Griso M, Perez-Labana F and Climente-Marti M. Evaluacion de dos sistemas cerrados en el proceso de elaboracion de quimioterapia parenteral. Farm Hosp. 2016; 40:36-43.
• Haifler M, Lang E, Sabler I, Gutman Y, Lindner A and Zisman A. Increasing medical staff safety by using a closed system for intravesical instillation of mitomycin C. Urology. 2010; 76:649-651.
• Hama K, Kitada N, Fukushima K, Hashida T and Kataoka K. Investigation on residual-related error and the effect of solution properties using protective devices for the reconstitution of cytotoxic agents in actual situations. J Oncol Pharm Practice. 2011; 17:55-60.
• Harrison BR, Peters BG and Bing MR. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health-Syst Pharm. 2006; 63:1736-1744
• Ho KV, Edwards MS, Solimando DA Jr, Johnson AD. Determination of extended sterility for single-use vials using the Phaseal closed-system transfer device. J Hematol Oncol Pharm. 2016; 6:46-50.
• Jorgenson JA, Spivey SM, Au C, Canann D, Ritter H and Smith B. Contamination comparison of transfer devices intended for handling hazardous drugs. Hosp Pharm. 2008; 43:723-727.
• Jorgenson JA and Stevenson JG. Special Report: Closed-system drug-transfer devices: ONB classification and the draft NIOSH protocol. Pharm Pract News. June 2017; Supp:1-4.
• Kelley L. Response to the study: ‘syringe plunger contamination by hazardous drugs: a comparative study’ by Stephen T Smith and Mark C Szlaczky. J Oncol Pharm Practice. 2014; 20:397-398.
• Kicenuik K, Northrup N, Dawson A, Locke J, Villamil JA, Chretin J, Sfiligoi G, Clifford C, Rosenberg M, Hamilton T, Regan R, Parsons-Doherty M, Mallett C, Philibert J, Imperllizeri J and Hofmeister E. Treatment time, ease of ue and cost associated with use of Equashield™, PhaSeal®, or no closed system transfer device for administration of cancer chemotherapy to a dog model. Vet Comp Oncol. 2015 (Epub ahead of print). DOI: 10.1111/vco.12148.
• Kopp B, Schierl R and Nowak D. Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings. Int Arch Occup Environ Health. 2013; 86:47-55.
• Koraleski M, Massoomi F and Zock M. Evaluation of FDA-approved ONB closed-system transfer devices utilizing Cyclophosphamide as a marker. ICU Medical Inc. 2013; M1-1455 Rev.01.
• Kunneva L. Closed system drug transfer devices for chemotherapy. Nursing. 2016; 46:67-68.
• Lamerie TQ, Carrez L, Decaudin B, Bouchoud L, Goossens JF, Barthelemy C, Bonnabry P and Odou P. Multiple-test assessment of devices to protect healthcare workers when administering cytotoxic drugs to patients. J Oncol Pharm Practice. 2011; 18:191-200.
• Le Garlantezec P, Rizzo-Padoin N, Aupee O, Lamand V, Broto H and Almeras D. Evaluation of the performance of transfer devices in a closed system using a radioactive solution of [(99m) Tc]. Ann Pharm Fr. 2011; 69:192-191 (French, English abstract).
• Massoomi F. The evolution of the CSTD. Pharm Purchasing and Products. 2015; 12 (2): S1-S12.
• Massoomi F and Eisenberg S. Pharmacy and nursing collaborate on CSTD training. Pharm Purchasing Prod. 2015; May:12-16.
• Mayer J, Menetre S, Serrurier C, Delfour A and May I. Comparison of closed-system devices for the preparation of cytotoxic drugs. Le Pharmacien Hospitalier et Clinicien. 2011; 46:116-122. (French, English abstract)
• Miyake T, Iwamoto T, Tanimura M and Okuda M. Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. SpringerPlus. 2013; 2:273.
• Mullot H, Blondeel S, Escalup L, Negellen S, Chenailler C, Pelloquin A and Courbard M. Interest and feasibility of Tevadaptor® and Phaseal® use in a centralized unit of antineoplastics preparation. Pharm Hosp. 2008; 43:189-199.
• Nygren O, Gustavsson B, Strom L, Eriksson R, Jarneborn L and Friberg A. Exposure to anti-cancer drugs during preparation and administration. Investigations of an open and a closed system. J Environ Monit. 2002; 4:739-732.
• Nygren O, Gustavsson B and Eriksson R. A test method for assessment of spill and leakage from drug preparation systems. Ann Occup Hyg. 2005; 49:711-718.
• Nygren O, Olofsson E and Johansson L. Spill and leakage using a drug preparing system based on double-filter technology. Ann Occup Hyg. 2008; 52:95-98.
• Nygren O, Olofsson E and Johannson L. NIOSH definition of closed-system transfer devices (Letter to the Editor). Ann Occup Hyg. 2009; 53:549.
• Nyman H, Jorgenson J and Slawson MH. Workplace contamination with antineoplastic agents in a new cancer hospital using a closed-system drug transfer device. Hosp Pharm. 2007; 42:219-225.
• Pérez-Minayo MF, Bazán EC, Segurado MH, Moya MAA, Torres PP and Martinez FJB. Use of closed systems in the hospital pharmacy. Farm Hosp. 2016; 40:102–17.
• Power LA. Closed-system transfer devices for safe handling of injectable hazardous drugs. Pharm Pract News. 2013;1-16.
• Rosenthal M. CSTD buyers need advocacy help. Pharm Prac News. 2016; April 4.
• Rosenthal M. CSTD test protocol stirs debate (Part 1) Pharm Pract News. February 2017; 44 (2):20-21.
• Rosenthal M. Establishing procedures for testing CSTDs (Part 2). Pharm Pract News. March 2017; 44 (3):32-33.
• Sanchez-Rubio Ferrrandez J, Lozano MC, Iglesias I, Sanchez-Rubio Ferrandez L, Rodriguez Vargas B and Moreno Diaz R. Use of a closed-system drug transfer device (PhaSeal®) and impact on preparation time. Int J Pharm Compd. 2012; 5:431-433.
• Sessink PJM, Rolf M-AE and Ryden NS. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm. 1999; 34:1311-17.
• Sessink PJM, Connor TH, Jorgenson JA and Tyler TG. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Practice. 2011; 17:39-48.
• Sessink PJM, Trahan J and Coyne JW. Reduction in surface contamination with cyclophosphamide in 30 hospital pharmacies following implementation of a closed-system drug transfer device. Hosp Pharm. 2013; 48:204-212.
• Siderov J, Kirsa S and McLauchlan R. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device. J Oncol Pharm Pract. 2010; 16:19-25.
• Sidikou O, Simon N, Sergent G, Vasseur M, Pinturaud M, Richeval C, Allorge D, Decaudin B and Odou P. In vitro assessment of a new extension set intended to reduce occupational exposure to antineoplastic drugs during hepatic chemoembolisation. Cardiovasc Intervent Radiol. 2015 (Epub ahead of print).
• Simon N, Vasseur M, Pinturaud M, Soichot M, Richeval C, Humbert L, Lebecque M, Sidikou O, Barthelemy C, Bonnabry P, Allorge D, Décaudin B and Odou P. Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug compounding unit: a prospective, controlled, parallel study. PLOS ONE. 2016; 11:e0159052.
• Simons A and Toland S. Closed systems for drug delivery: a necessity, not an option. Brit J Nurs. 2015; 24:S20,S22.
• Smith ST and Szlaczky MC. Syringe plunger contamination by hazardous drugs: a comparative study. J Oncol Pharm Practice. 2014; 20:381-385.
• Smith ST and Szlaczky MC. Response to the editor. J Oncol Pharm Practice. 2014; 20:399-400.
• Spivey S and Connor TH. Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system. Hosp Pharm. 2003; 38:135-139.
• Tans B and Willems L. Comparative contamination study with cyclophosphamide, fluorouracil and ifosfamide: standard versus a proprietary closed-handling system. J Oncol Pharm Practice. 2004; 10:217-223.
• Vandenbroucke J and Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Practice. 2001; 6:146-152.
• Vyas N, Turner A, Clark JM and Sewell GJ. Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator. J Oncol Pharm Practice. 2014; (Epub ahead of print) DOI: 10.1177/1078155214544993.
• Vyas N, Yiannakis D, Turner A and Sewell GJ. Occupational exposure to anti-cancer drugs: A review of effects of new technology. J Oncol Pharm Pract. 2014; 20:278-287.
• Wakui N, Ookubo T, Iwasaki Y, Ito R, Saito K and Nakazawa H. Development of a closed drug preparation method for oral anticancer drugs. J Oncol Pharm Practice. 2013; 19:315-320.
• Wick C, Slawson MH, Jorgenson JA and Tyler LS. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health-Syst Pharm. 2003; 60:2314-2320.
• Wilkinson A-S, Allwood MC, Morris CP, Wallace A, Finnis R, Kaminska, E and Hemingway, M. Performance testing protocol for closed-system transfer devices used during pharmacy compounding and administration of hazardous drugs. PLOS ONE 2018; 13:1-15.
• Yoshida J, Tei G, Mochizuki C, Masu Y, Koda S and Kumagai S. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Ann Occup Hyg. 2009; 53:153-160.
• Zock MD, Soefje S and Rickabaugh K. Evaluation of surface contamination with cyclophosphamide following simulated hazardous drug preparation activities using two closed-system products. J Oncol Pharm Practice. 2011; 17:49-54.

Several approaches have been developed for evaluating work practice techniques for drug preparation and drug administration. These approaches typically rely on a non-toxic substitute for the drug that can be easily visualized by ultra violet light or other means. Some test kits are available for various manufacturers.

• Friese CR, Himes-Ferris L, Frasier MN, McCullagh MC, Griggs JJ. Structures and processes of care in ambulatory oncology settings and nurse-reported exposure to chemotherapy. BMJ Qual Saf. 2012; 21:753-759.
• Georgiadi A, Rämme E, Wretman C and Eksborg S. How to create acceptable working conditions for hospital pharmacy staff when preparing cytotoxic drugs. Eur J Hosp Pharm. 2004; 3:40-42.
• Guillemette A, Langlois H, Voisine M, Merger D, Therrien R, Mercier G, Lebel D and Bussieres JF. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device. J Oncol Pharm Practice. 2014; 20:426-432.
• Harrison BR, Godefroid RJ and Kavanaugh EA. Quality-assurance testing of staff pharmacists handling cytotoxic agents. Am J Health-Syst Pharm. 1996; 53:402-407.
• Keat CH, Sooaid NS, Yun CY and Sriraman M. Improving safety-related knowledge, attitude and practices of nurses handling cytotoxic anticancer drugs: Pharmacists’ experience in a general hospital, Malaysia. Asian Pac J Cancer Prev. 2013; 14:69-73.
• Kopp B, Schierl R and Nowak D. Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings. Int Arch Occup Environ Health. 2013; 86:47-55.
• Kromhout H, Hoek F, Uitterhoeve R, Huijbers R, Overmars RF, Anzion R and Vermeulen R. Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg. 2000; 44:551-560.
• Spivey S and Connor TH. Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system. Hosp Pharm. 2003; 38:135-139.
• Van Raalte J, Rice C and Moss E. Visible-light system for detecting doxorubicin contamination on skin and surfaces. Am J Hosp Pharm. 1990; 47:1067-1074.